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ABSTRACT
Objective: The aim of this study was to examine in vitro antimicrobial activity of a series of 7-benzamidocoumarin derivatives against three Gram-
positive bacteria (Bacillus subtilis, Staphylococcus aureus, and Bacillus pumilus), three Gram-negative bacteria (Escherichia coli, Klebsiella pneumonia, 
and Salmonella typhi), and three fungi (Candida albicans, Candida tropicalis, and Aspergillus niger) by 2-fold serial dilution method.
Materials and Methods: The compounds were synthesized by amide coupling of 7-amino-4-methyl coumarin 5 and 7-amino-4-chloromethyl 
coumarin 6 with different aromatic acids 7 (a-h) and heteroaromatic acids 8 (i-j) in the presence of phosphorous trichloride as an acid catalyst in 
acetonitrile. The synthesized compounds were evaluated for antimicrobial and chitinase inhibitory activity.
Results: Compounds 9, 11, 12, 21, and 23 showed good antibacterial activity with minimum inhibitory concentration (MIC) ranging from 6.25 to 
50 µg/mL. Among them, compound 21 was the most active molecule with MIC 6.25 µg/mL against S. aureus and 6.25 µg/mL against, B. pumilus 
and S. typhi. Compounds 11 and 21 were the most potent antifungal candidates with MIC 6.25–25 µg/mL against C. albicans and C. tropicalis. All the 
compounds were also evaluated for their chitinase inhibitory property and among them; compound 9 emerged as strong inhibitor of the enzyme.
Conclusion: Some of the compounds showed very good antimicrobial activities. Among these, compound 21 showing potent antimicrobial activities 
against five of the nine microbial strains examined in this study, was the most active compound of the series. Some of the compounds also showed 
chitinase inhibitory properties. This study also provides a starting point for investigating the structure-activity relationships (SARs) of synthetic 
7-benzamidocoumarins.
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INTRODUCTION
Over the past decade, the incidence of bacterial infections has 
increased worldwide, particularly in Indian subcontinent, portions 
of South America, and tropical fraction of Africa [1,2]. In spite of the 
availability of a large number of antibiotics and chemotherapeutics, 
the treatment of bacterial diseases still remains a challenging problem 
due to a number of factors such as the emergence of drug-resistant 
strains, severe adverse effects, narrow antibacterial spectrum, and 
association of microbial infections with other diseases mainly in 
immunocompromised patients [3-5]. Despite the major cause of 
morbidity and mortality, these infections are given low priority, and 
most importantly, the pipeline for new antibiotics has paradoxically 
experienced a long-term decline [6].
Fungal infections also pose a continuous and serious threat to 
human health and life. It is estimated that about 1.2 billion people 
worldwide suffer from fungal diseases [7]. The opportunistic 
fungal pathogens belonging to Candida spp., Cryptococcus spp., and 
Aspergillus spp. account for the majority of documented invasive 
fungal infections in humans. These infections are responsible for 
high morbidity and mortality in immune-compromised patients such 
as those undergoing organ transplants or anticancer chemotherapy 
and patients with AIDS [8]. The existing mainstay antifungal drugs 
such as fluoroquinolones, amphotericin-B (Amp), and azoles are 
associated with a number of severe side effects and development of 
resistance [9]. Thus, there is a pressing need for the development 
of alternative antimicrobial drugs involving new molecules with a 
broader spectrum and less side effects.
Coumarins are a group of oxygen-containing heterocyclic compounds 
with a benzoannelated α-pyrone ring. They are found in a large number 
of bioactive natural and non-natural molecules. Due to structure 
variability, low toxicity, and low cost, coumarins play an important 
role in modern drug discovery and synthetic chemistry. Coumarin 
derivatives display a wide range of biological activities such as 
antimalarial, antimicrobial, anticancer, anti-inflammatory, antioxidant, 
antiviral, antitubercular, and antifilarial [10,11]. The pharmacological, 
biochemical, and therapeutical potential of coumarin compounds 
mainly depend on the substituent they bear on their basic chemical 
skeleton [12]. Another, unique feature of coumarin, which makes it a 
privileged structural framework, is its ability to interact readily with 
a diversity of enzymes and receptors in organisms through weak bond 
interactions. Therefore, substitution on the lactone and aromatic 
rings of a coumarin motif provides opportunities for modulation of 
biological activities and enhancement in pharmacokinetic properties. 
In recent years, coumarin derivatives have gained tremendous 
attention due to their applications in drug design and discovery [13,14]. 
Keeping in view of the above and in continuation of our work on the 
design and synthesis of coumarin compounds possessing antimicrobial 
and antifilarial properties [15,16], we report herein the synthesis 
and antimicrobial activity of a series of 7-benzamidocoumarins. 
The synthesized compounds were also evaluated for their chitinase 
inhibitory activity. To carry out this study, first, we screened six simple 
coumarin scaffolds for their antimicrobial properties. Out of these, the 
4-methyl-and 4-chloromethyl-7-aminocoumarins which showed the 
best activity were chosen as starting material for further optimization 
study. We hope this study may be useful in further design of coumarin-
based molecules as antimicrobial drugs or prodrugs.
MATERIALS AND METHODS
Unless otherwise stated, all materials were obtained from commercial 
suppliers (SRL and Spectrochem Pvt., Ltd.) and were used without 
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further purification. Melting points were determined on a Buchi 
510 apparatus and are uncorrected. Silica gel (60–120 mesh) from 
commercial supplier Spectrochem Pvt., Ltd. was used for column 
chromatography. Thin-layer chromatography was used to monitor the 
reactions, and the spots were visualized by spraying KMnO4 reagent. IR 
spectra were recorded on JASCO FTIR 5300 in KBr from 400 to 4000 
cm−1. NMR spectra were recorded on JEOL AL 300 FT-NMR spectrometer 
using tetramethylsilane as an internal standard. The chemical shift 
values are on δ scale and the coupling constant (J) is in hertz (Hz).
Synthetic procedure
4-methyl-7-hydroxy-6-nitrocoumarin 4
4-Methyl-7-hydroxycoumarin (250 mg) was dissolved in 2 mL of conc. 
sulfuric acid at room temperature and cooled at 0°C. To this solution, 
a chilled nitrating mixture (3 mL of concentrated nitric acid added to 
9 mL of concentrated sulfuric acid) was added. The solution was stirred 
at 0°C for 3 h and then poured over crushed ice. The precipitated 
bright yellow product was filtered off, washed with ice cold water 
and recrystallized from ethanol to give compound 4 as yellow, green 
crystals [17].
7-Amino-4-methyl-2H-chromen-2-one 5
First, ethyl (3-hydroxyphenyl) carbamate was prepared by the following 
method: To stirred suspension of 3-aminophenol (5 g, 45.5 mmol) in 
20 mL of anhydrous diethyl ether, ethyl chloroformate (6 g, 54.6 mmol) 
was added. The reaction mixture was stirred for 2 h at room temperature. 
After the completion of the reaction, the amine hydrochloride was 
removed by filtration. The filtrate was then evaporated to give off 
white solid, which was recrystallized from petroleum ether to afford 
carbamate derivative as white crystalline solid. To the stirred solution 
of the carbamate (2.0 g, 11.0 mmol) in 25 mL of 70% H2SO4 in ethanol 
(18 mL H2SO4 + 7 mL EtOH), ethyl acetoacetate (2.18 g, 13.25 mmol) 
was added and the reaction mixture was stirred at room temperature 
for 4 h. The mixture was then poured in 50 mL of ice cold water, 
giving ethyl (4-[methyl]-2-oxo-2H-chromen-7-yl) carbamate as white 
precipitate that was crystallized from absolute EtOH. Ethyl (4-chloro-
methyl-2-oxo-2H-chromen-7-yl) carbamate was also prepared by the 
same procedure using ethyl chloro acetoacetate.
In the next sequence of reaction, 7-carbethoxyamino-4-methyl 
coumarin (1.5 g, 5.33 mmol) was dissolved in a solution of 10 mL of 
concentrated H2SO4 and 10 mL of glacial acetic acid. The mixture was 
heated at reflux for 2 h. After cooling to room temperature, the mixture 
was poured in 50 mL of ice cold water. At 0°C, 50% NaOH was added 
until the solution resulted slightly alkaline (pH = 9–10). The obtained 
precipitate was filtered and washed with ice cold water (10 mL) to 
afford the desired 7-amino-4-methyl-2H-chromen-2-one 5 as light 
yellow solid [18,19].
7-amino-4-chloromethyl-2H-chromen-2-one (6)
The reaction of 7-carbethoxyamino-4-chloromethyl coumarin 
(2.5 g, 13.8 mmol) in the presence of 2 mL of concentrated H2SO4 and 
2 mL of glacial acetic acid under reflux condition for a period of 2 h as 
described above gave 7-amino-4-chloromethyl-2H-chromen-2-one 6 as 
light brown solid.
General procedure for the synthesis of 7-benzamidocoumarin 
derivatives 9–23
Amino coumarins 5 and 6 (1 mmol) and appropriate aromatic acids 
7 (a-h) or hetero-aromatic acids 8 (i-j) (1.2 mmol) were dissolved in 
acetonitrile (5 mL), PCl3 (1 mmol) and the reaction mixture was refluxed 
for 3–6 h. After completion of the reaction, the reaction mixture was 
quenched with a few drops of water. The solvent was evaporated; the 
residue was dissolved in ethyl acetate (10 mL) and washed twice with 
saturated NaHCO3 solution. The organic layer was dried over Na2SO4 
and the solvent was evaporated under reduced pressure. The crude 
product was purified by column chromatography on silica gel using 2% 
CH3OH in CHCl3 solvent system as mobile phase [20].
Determination of MIC
Synthesized compounds were evaluated on the basis of their 
antimicrobial activities examined in terms of MIC against six multiple 
drug-resistant bacterial test strains, namely B. subtilis MTCC 121, 
S. aureus MTCC 96, B. pumilus MTCC 1607, K. pneumoniae MTCC 3384, 
S. typhi MTCC 537, and E. coli MTCC1304 and three fungi C. albicans 
MTCC 3017, C. tropicalis MTCC 184, and A. niger MTCC 1344. MIC is 
the lowest concentration of the compound that will be able to inhibit 
the microbial growth under experimental conditions. Erythromycin 
(Ery) and Amp were used as standards for antibacterial and antifungal 
activity, respectively.
MIC of the synthesized compounds was determined by the micro 
broth dilution method using 96 well plates according to the method 
described by Vipra et al. [21] with some modification. The bacterial 
test organisms were grown in sterile nutrient broth (NB) at 30°C. From 
this stock solution certain inoculums were used to inoculate fresh 
medium, and the final inoculum size for test strains was adjusted to 
106 cfu/mL (colony-forming unit per milliliter). Fresh NB was taken as a 
negative control in the first well, whereas NB with test organisms were 
consider as a positive control in the last well. Stock solutions of 1 mg/mL 
of compounds were prepared. From this, 100 μg/mL concentrations 
were taken as starting solution in the second well and diluted serially 
up to the second last well. Microtiter plates were incubated at 30°C for 
overnight under the static condition and read using ELISA plate reader. 
Well containing the lowest concentration of the compounds at which no 
turbidity was observed consider as MIC.
Chitinase assay for coumarin derivatives
Chitinase inhibitory activity of the coumarin compounds was 
determined by Dinitrosalicylic acid (DNS) as mentioned by Miller 
using colloidal chitin as a substrate [22]. Colloidal chitin was prepared 
from the chitin powder. Five grams of chitin powder (C8H13O5N) were 
gradually mixed with 6 mL concentrated HCl (32%) and incubated at 
room temperature with vigorous stirring for about 2 h on an orbital 
shaker. Ice-cold water was added to precipitate the chitin and this 
solution was further incubated overnight. After incubation, it was 
centrifuged at 10,000 rpm for 20 min at 4°C. The pellet was washed 
repeatedly with distilled water until the pH of the chitin suspension 
reached the pH of distilled water. Finally, the substrate was autoclaved 
and stored at 4°C.
Reaction mixture containing 100 µl of coumarin compound (stock 
solution 1 mg/ml), 1 ml colloidal chitin and 1 ml chitinase extracted 
from actinomycetes strain were taken in test tubes and incubated for 
30 min at 37°C in shaking water bath. The reaction was stopped by 
adding 2 ml DNS reagent and kept in a boiling water bath for 5 min 
to develop the color. After cooling the test tubes for 10 min; color was 
observed against control. The concept lies in DNS reaction is the change 
in color from yellowish orange to brownish orange.
RESULTS AND DISCUSSION
Chemistry
Compounds 1–3 were purchased from the commercial supplier and 
used without further purification. Compound 4 was synthesized by 
nitration of 4-methyl-7-hydroxycoumarin under cold condition by 
earlier reported method [17]. Compounds 5 and 6 were prepared 
by following method. In the first step, protected amino phenol was 
synthesized by reaction of 3-amino phenol with ethylchloroformate 
in presence of K2CO3. The protected amino phenol on Pechmann 
condensation with ethyl acetoacetate and ethyl 4-chloroacetoacetate 
in the presence of 70% ethanolic H2SO4 at room temperature followed 
by deprotection of carbamate group using mixture of H2SO4 and 
CH3COOH (1:1) afforded 7-amino-4-methyl coumarin 5 and 7-amino-4-
chloromethyl coumarin 6, respectively, in good yields [18,19]. With the 
desired amino coumarins 5 and 6 in hand, the synthesis of 7-benzamide-
coumarins was undertaken. 7-benzamido-4-methyl-coumarins 9–11 
were obtained by reaction between 7-amino-4-methyl coumarin 5 and 
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substituted salicylic acids 7 a-c in CH3CN in the presence of PCl3 under 
reflux condition while compounds 12–14 and 15 were prepared by 
the reaction of 7-amino-4-chloromethyl coumarin 6 with substituted 
salicylic acids 7a-c and unsubstituted salicylic acid 7d, respectively. 
Further, the synthesis of amidocoumarins 16–19 was carried out 
by reaction between compound 6 and benzoic acid derivatives 
7 (e-h) bearing electron releasing and electron withdrawing groups 
as described above (Scheme 1). In the next sequence of reactions, few 
heteroaromatic acids such as 2-picolinic acid 8i and 2-pyrazinoic acid 
8j were selected to synthesize 7-amidocoumarins 20–23 (Scheme 1). 
The spectroscopic data of all the compounds reported herein were 
found to be in good agreement with previously published data [20]. As 
a representative example, the structure elucidation of compound 19, 
obtained by the reaction between 7-amino-4-chloromethyl coumarin 
6 and 2-methyl benzoic acid 7 h is described here. The compound 
exhibited absorption bands at 3331 and 1714 cm−1 in the IR spectrum 
for N-H stretching and δ-lactone, respectively. In 1H NMR spectrum, -NH 
proton appeared at δ 10.3 as broad singlet while signal corresponding 
to H-6’ proton of benzamide ring was observed as multiplet at δ 7.94. 
Doublet appeared at δ 7.81 with coupling constant of 2.4 Hz was due to 
the H-8 proton of the benzamide ring, whereas doublets at δ 7.61 and 
δ 7.50 with a coupling constant of 8.7 Hz were due to the H-5 and H-6 
protons of benzopyrone ring, respectively. Signal due to H-4’ was found 
as multiplet at δ 7.38 while multiplet at δ 7.29 was ascribed to the H-3’ 
and H-5’ protons of the benzamide ring. Singlets at δ 6.45, 4.69, and 
2.38 were assigned to H-3 of lactone ring, methylene protons (−CH2Cl), 
and methyl group at C-2’ carbon, respectively.
4-Methyl-7-hydroxy-6-nitrocoumarin (4)
Yield: 78%; mp: 195°C–196°C; IR (KBr): 3125, 3060, 1730, 1620, 1530, 
1390 cm−1.1H NMR (DMSO-d6, 300 MHz): δ 2.38 (s, 3H, CH3), 6.41 (s, 1H), 
7.40 (s, 1H), 8.48 (s, 1H).
7-Amino-4-methyl-2H-chromen-2-one (5)
71%; mp 223°C–224°C (lit. mp: 220°C–222°C18);1H NMR (DMSO-d6, 
400 MHz) δ: 2.39 (s, 3H), 5.92 (s, 1H), 6.10 (brs, 2H), 6.37 (s, 1H), 6.58 
(m, 1H), 7.36 (d, J = 8.8 Hz, 1H).
7-amino-4-chloromethyl-2H-chromen-2-one (6)
Yield: 70%; 1H NMR (DMSO-d6, 300 MHz) δ: 4.85 (s, 2H), 6.16 (s, 1H), 
6.22 (s, 2H), 6.40 (d, J = 2.2 Hz, 1H), 6.58 (dd, J = 8.8 and 2.2 Hz, 1H), 
7.47 (d, J = 8.8 Hz, 1H).
2-hydroxy-N-(4-methyl-2-oxo-2H-chromen-7-yl)-3,5-dinitrobenzamide (9)
Light yellow solid; yield: 75%; mp: 153-154 °C; IR (cm-1, KBr) νmax: 
3323, 1718, 1532, 1356;1H NMR (DMSO-d6, 500 MHz) δ: 2.36 (s, 3H, 
CH3), 6.46 (s, 1H), 7.25 (d, J = 1.5 Hz, 1H), 7.88 (d, J = 8.5 Hz, 1H), 7.93 
(m, 2H), 8.57 (s, 1H), 9.65 (s, 1H).
2-hydroxy-3,5-diiodo-N-(4-methyl-2-oxo-2H-chromen-7-yl) benzamide (10)
Off white solid; yield: 79%; mp: 176°C–178°C; IR (cm−1, KBr) νmax: 3341, 
1708, 1528, 1349;1H NMR (DMSO-d6, 500 MHz) δ: 2.38 (s, 3H, CH3), 
6.18 (s, 1H, H-3), 7.36 (d, J = 9.0 Hz, 1H), 7.67 (d, J = 8.5 Hz, 1H), 7.73 
(d, J = 2.0 Hz, 1H), 7.92 (s, 1H), 7.95 (s, 1H).
3,5-dibromo-2-hydroxy-N-(4-methyl-2-oxo-2H-chromen-7-yl) 
benzamide (11)
Off white solid; yield: 80%; mp: 165°C–167°C; IR (cm−1, KBr) νmax: 3366, 
1700, 1534, 1348;1H NMR (DMSO-d6, 500 MHz) δ: 2.38 (s, 3H), 6.18 (s, 
1H), 7.34 (d, J = 8.5 Hz, 1H), 7.66 (d, J = 8.5 Hz, 1H), 7.81 (m, 2H), 7.95 
(s, 1H), 15.21 (s, 1H).
N-(4-[chloromethyl]-2-oxo-2H-chromen-7-yl)-2-hydroxy-3,5-dinitro 
benzamide (12)
Yellow solid; yield: 78%; mp: 140°C–142°C; IR (cm−1, KBr) νmax: 3343, 
1711, 1569, 1349;1H NMR (DMSO-d6, 500 MHz) δ: 4.95(s, 2H), 6.72 
(s, 1H), 7.47 (m, 2H), 7.79 (s, 1H), 8.02 (d, J = 2.0 Hz, 1H), 8.61 (s, 1H), 
10.85 (s, 1H, NH).
N-(4-[chloromethyl]-2-oxo-2H-chromen-7-yl)-2-hydroxy-3,5-diiodo 
benzamide (13)
Off white solid; yield: 80%; mp: 169°C–170°C; IR (cm−1, KBr) νmax: 3331, 
1699, 1619, 1336;1H NMR (DMSO-d6, 500 MHz) δ: 4.96 (s, 2H), 6.57 
(s, 1H), 7.71 (d, J = 2.0 Hz, 1H), 7.80 (m, 2H), 8.20 (m, 2H).
3,5-dibromo-N-(4-[chloromethyl]-2-oxo-2H-chromen-7-yl)-2-hydroxy 
benzamide (14)
Off white solid; yield: 79%; mp: 166°C–168°C; IR (cm−1, KBr) νmax: 3314, 
1701, 1528, 1345;1H NMR (DMSO-d6, 500 MHz) δ: 4.94 (s, 2H), 6.53 
(s, 1H), 7.54 (dd, J = 8.5 and 2.0 Hz, 1H), 7.68 (d, J = 2.0 Hz, 1H), 7.72 
(d, J = 8.5 Hz, 1H), 8.34 (d, J = 2.0 Hz, 1H), 8.46 (d, J = 2.0 Hz, 1H), 10.85 
(s, 1H).
N-(4-[chloromethyl]-2-oxo-2H-chromen-7-yl)-2-hydroxybenzamide (15)
Colorless solid; yield: 82%; mp: 146°C–147°C; IR (cm−1, KBr) νmax: 3371, 
1728, 1578, 1228;1H NMR DMSO-d6, 500 MHz) δ: 4.96(s, 2H), 6.54 
(s, 1H), 6.94 (m, 2H), 7.39 (m, 1H), 7.67 (m, 2H), 7.89 (m, 2H), 10.84 (s, 1H).
N-(4-[chloromethyl]-2-oxo-2H-chromen-7-yl) benzamide (16)
Colorless solid; yield: 81%; mp: 137°C–139°C; IR (cm−1, KBr) νmax: 
3431, 1722, 1594, 1338;1H NMR (CDCl3, 300 MHz) δ: 4.60 (s, 2H), 6.56 
Scheme 1: Synthesis of 7-amidocoumarins
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(s, 1H), 7.16 (m, 1H), 7.35 (m, 2H), 7.47 (m, 1H), 7.66 (m, 1H), 7.71 
(m, 3H).
2-chloro-N-(4-[chloromethyl]-2-oxo-2H-chromen-7-yl) benzamide (17)
Colorless solid; yield: 81%; mp: 146°C–147°C; IR (cm−1, KBr) νmax: 3421, 
1732, 1591, 1261;1H NMR (CDCl3, 300 MHz) δ: 4.62(s, 2H), 6.60 (s, 1H), 
7.19 (m, 2H), 7.41 (m, 4H), 7.69 (d, J = 8.4 Hz, 1H).
N-(4-[chloromethyl]-2-oxo-2H-chromen-7-yl)-2-methoxybenzamide (18)
Colorless solid; yield: 80%; mp: 160°C–162°C; IR (cm−1, KBr) νmax: 3317, 
1726, 1587, 1298;1H NMR (CDCl3, 300 MHz) δ: 3.18 (s, 3H), 4.27(s, 2H), 
5.86 (s, 1H), 6.37 (m 1H), 6.50 (m, 1H), 6.82 (m, 1H), 6.94 (m, 2H), 7.12 
(d, J = 8.5 Hz, 1H), 7.24 (m 1H), 9.87 (s, 1H).
N-(4-[chloromethyl]-2-oxo-2H-chromen-7-yl)-2-methylbenzamide (19)
Colorless solid; yield: 84%; mp: 149°C–151°C; IR (cm−1, KBr) νmax: 3331, 
1713, 1582, 1250;1H NMR (CDCl3, 300 MHz) δ: 2.38 (s, 3H), 4.69 (s, 2H), 
6.45 (s, 1H), 7.29 (m, 2H), 7.38 (m, 1H), 7.50 (d, J = 8.7 Hz, 1H), 7.61 
(d, J = 8.7 Hz, 1H), 7.81 (d, J = 2.4 Hz, 1H), 7.94 (m, 1H), 10.3 (s, 1H).
N-(4-methyl-2-oxo-2H-chromen-7-yl) picolinamide (20)
Colorless solid; Yield: 83%; mp: 180°C–182°C; IR (cm−1, KBr) νmax: 3324, 
1713, 1572, 1323;1H NMR (DMSO-d6, 500 MHz) δ: 2.36 (s, 3H, CH3), 5.32 
(s, 1H, H-3), 6.78 (m, 1H), 6.78 (d, J = 8.5 Hz, 1H), 6.93 (dd, J = 8.5 and 
2.0 Hz, 1H), 7.17 (m, 1H), 7.29 (m, 2H), 7.86 (d, J = 4.5 Hz, 1H), 9.84 
(s, 1H, NH).
N-(4-[chloromethyl]-2-oxo-2H-chromen-7-yl) picolinamide (21)
Off white solid; yield: 82%; mp: 184°C–186°C; IR (cm−1, KBr) νmax: 
3329, 1745, 1623, 1332;1H NMR (DMSO-d6, 500 MHz) δ: 4.95 (s, 2H), 
6.54 (s, 1H), 7.68 (m, 1H), 7.79 (d, J = 9.0 Hz, 1H), 7.92 (d, J = 9.0 Hz, 1H), 
8.1 (s, 1H), 8.09 (m, 1H), 8.17 (d, J = 7.5 Hz, 1H), 8.72 (d, J = 4.0 Hz, 1H), 
11.05 (s, 1H, NH).
N-(4-methyl-2-oxo-2H-chromen-7-yl) pyrazine-2-carboxamide (22)
Light yellow solid; yield: 81%; mp: 170°C–171°C; IR (cm−1, KBr) νmax: 
3428, 1710, 1615, 1391;1H NMR (DMSO-d6, 300 MHz) δ: 2.39 (s, 3H), 
6.23 (s, 1H), 7.64 (m, 1H), 7.75 (m, 1H), 7.96 (s, 1H), 8.69 (s, 1H), 8.84 
(s,1H), 9.46 (s, 1H), 10.21 (s, 1H).
N-(4-[chloromethyl]-2-oxo-2H-chromen-7-yl) pyrazine-2-carboxamide (23)
Off white solid; yield: 81%; mp: 179°C–180°C; IR (cm−1, KBr) νmax: 3304, 
1708, 1617, 1332;1H NMR (DMSO-d6, 500 MHz) δ: 4.94 (s, 2H), 6.54 
(s, 1H), 7.86 (m, 2H), 8.1 (d, J = 1.5 Hz, 1H), 8.82 (d, J = 2.0 Hz, 1H), 8.91 
(d, J = 2.0 Hz, 1H), 9.28 (d, J = 2.0 Hz, 1H), 11.2 (s, 1H).
Antimicrobial activity
First, we evaluated six simple coumarins 1–6 against three Gram-
positive bacterial strains B. subtilis MTCC 121(Bs), S. aureus MTCC 96 
(Sa), and B. pumilus MTCC1607 (Bp) and three Gram-negative strains 
E. coli MTCC1304 (Ec), K. pneumoniae MTCC 3384(Kp), and S. typhi 
MTCC 537 (St) to determine the best skeleton for further modification. 
Out of these compounds, aminocoumarins 5 and 6 exhibited superior 
activity against the tested strains as compared to compounds 1–4 
(Table 1). Therefore, compounds 5 and 6 were selected for further 
molecular optimization. Using amino coumarins 5 and 6 as basic 
skeleton, 7-amidocoumarins 9–23 were synthesized and examined for 
their MIC by the two-fold serial microdilution method using clinically 
antibacterial drug Ery standard [23] against the same above stated 
bacterial strains. The results are shown in Table 2 and Figs. 1 and 2. The 
MIC was defined as the lowest concentration of the tested compound 
at which no growth of the strain was observed in a period of time and 
under specified experimental conditions.
As shown in Table 2, among the 4-methyl series, compounds 9 and 
11 bearing dinitro and dibromo substituted salicylic acid residue, 
respectively,  showed MIC 12.5 μg/mL against B. pumilus and K. 
pneumonia. Compound 11 showed superior activity against B. subtilis 
(6.25 μg/mL) as compared to compound 9(25 μg/mL). Compounds 12–
15 bearing 4-chloromethyl group showed low order of activity against 
all the tested strain with MIC’s in the range of 25–200 μg/mL. Further, 
compounds 16–19 bearing unsubstituted benzoic acid, chloro, methoxy, 
and methyl substituted benzoic acid residue, respectively, showed inferior 
activity or even no inhibition against all the tested bacterial strains with 
MIC values in the range of 50 to >200 µg/mL. Further, the role of salicylic 
acid residue was explored with the synthesis and compounds 20–23 
bearing heteroaromatic acid substituent. The activity was improved with 
the introduction of pyridinyl and piperazinyl ring, but surprisingly, in 
this case, 4-chloromethyl group bearing compounds exhibited superior 
activity than the 4-methyl group-containing compounds (21 and 23 vs. 20 
and 22). Compound 21 bearing 4-chloromethyl and pyridinyl substituent 
showed superior activity among all the tested compounds and was found 
to be the most active compound of the series. It showed activity against 
four bacterial strains with MIC ranging from 6.25 to 25 µg/mL. Its potency 
against S. typhi was comparable to the standard drug Ery. Compound 23 
exhibited activity at a concentration of 6.25 and 12.5 µg/mL against B. 
pumilus and K. pneumoniae, respectively. Altogether, in these compounds, 
SARs revealed that the antibacterial activity improved by replacing 
the benzoic acid substituent with a salicylic acid substituent. Further, 
compounds containing 4-methyl substituent showed superior activity 
than the corresponding 4-chloromethyl group bearing compounds 
(compounds 9–11 vs. compounds 12–14). Interestingly, compounds 
21 and 23 containing heteroaromatic ring and chloromethyl group as a 
substituent at the fourth position of coumarin ring were found to be more 
active than the corresponding 4-methyl group-containing compounds 20 
and 22.
The synthesized compounds were also evaluated against three fungal 
strains C. albicans, C. tropicalis, and A. niger. The results are summarized 
in Table 2 and Fig. 3. For C. albicans, MIC values of these compounds 
vary from 6.25 to 200 µg/mL. Among these, compounds 9, 11, 21, and 
Fig. 1: Antibacterial activity of amidocoumarins against Gram-
positive bacteria
Fig. 2: Antibacterial activity of amidocoumarins against Gram-
negative bacteria
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Table 1: Antibacterial activity of compounds 1-6 expressed as a minimum inhibitory concentration (μg/mL)













Bs 200 100 100 100 100 50 <3.25
Sa 200 200 100 50-100 50 50 2.75
Bp 200 100 100 100 100 25 1.5
Ec 200 200 200 200 >200 200 9.63
Kp >200 >200 >200 >200 200 100 <0.39
St 200 100 100 100 25 25 6.78
aErythromycin
Table 2: Antimicrobial activities of 7-amidocoumarins as expressed in minimum inhibitory concentration (μg/mL)
Compound number Gram-positive Gram-negative Caa Cta Ana
Bsa Saa Bpa Eca Kpa Sta
9 25 100 12.5 200 12.5 200 12.5 25 6.25
10 50 100 50 >200 25 100 100 >200 200
11 6.25 50 12.5 50 12.5 25 6.25 6.25 25
12 100 100 25 200 200 50 100 >200 200
13 100 200 100 100 >200 >200 200 >200 200
14 50 100 50 >200 100 25 200 100 100
15 200 >200 50 100 200 50 200 >200 200
16 200 200 200 >200 >200 200 200 >200 200
17 100 >200 200 100 200 100 200 100 200
18 100 >200 200 100 200 50 200 >200 200
19 50 100 200 200 200 100 200 >200 200
20 200 50 100 200 100 200 200 >200 100
21 12.5 6.25 6.25 100 50 6.25 12.5 25 50
22 100 100 200 >200 >200 100 50 200 200
23 100 50 6.25 50 12.5 25 12.5 50 25
Ery <3.25 2.75 1.5 9.63 <0.39 6.78 - - -
Amp - - - - - - 6.25 12.5 6.25
aBacillus subtilis (Bs, MTCC 121), Staphylococcus aureus (Sa, MTCC 96), Bacillus pumilus (Bp, MTCC 1607), Escherichia coli (Ec, MTCC1304), Klebsiella pneumonia (Kp, 
MTCC 3384), Salmonella typhi (St, MTCC 537), Candida albicans (Ca, MTCC 3017), Candida tropicalis (Ct, MTCC 184), Aspergillus niger (An, MTCC 1344)
23 showed the highest activity (6.25–50 μg/mL). Compound 11 was 
equipotent to Amp against C. albicans and exhibited two-fold superior 
activity against C. tropicalis than the standard drug Amp. The MICs of 
these four compounds against A. niger were found to be in the range of 
6.25–50 µg/mL. Compound 9 showed promising activity (6.25 µg/mL) 
against A. niger.
Chitinase Inhibitory activity
Chitin, the linear polymer of N-acetylglucosamine, is an essential structural 
component of the fungal cell wall. Fungal chitinases play an important 
role in exogenous chitin decomposition, fungal cell wall degradation, 
and remodeling. These enzymes have been proposed as an important 
target for the design and development of novel antifungals [24]. Several 
chitinase inhibitors have been reported in literature, but none of them has 
yet successfully reached the clinic for the treatment of fungal infections 
[25,26]. Therefore, there is an urgent need for the identification of novel 
chitinase inhibitors. In this study, the coumarin derivatives 9–23 were also 
tested for their anti-chitinase activity. Chitinase activity of the compounds 
was determined by DNS, as mentioned by Miller using colloidal chitin as a 
substrate [22]. Here, the concept lies in DNS color change from yellowish 
orange to brownish orange. During the reaction, chitinase breaks colloidal 
chitin into N-acetyl glucosamine (NAG), a reducing sugar liberated from 
the hydrolysis of chitin polymer. This reducing sugar binds with DNS to 
impart a brown color to the solution. If the compound is inhibitory in 
nature toward chitinase the basic color of DNS does not change and NAG 
is not formed but if the compound is noninhibitory in nature; it does not 
interfere in the normal reaction between chitinase and colloidal chitin and 
change in color is reflected. In our study, compounds 9, 16, 18, 21, and 
23 were found to inhibit the enzyme chitinase because, after incubation 
with these compounds, the enzyme became ineffective to breakdown 
the colloidal chitin and the basic color of DNS did not change. However, 
the other coumarin compounds of the series exhibited non-inhibitory 
behavior toward the chitinases, i.e., the compounds did not interfere in 
the normal reaction of chitinase with colloidal chitin and color change was 
observed. Among the tested compounds, compound 9 was found to be the 
most effective chitinase inhibitor.
CONCLUSION
In summary, we synthesized a series of 7-benzamidocoumarins and 
reported their antimicrobial activity for the first time. Some of these 
Fig. 3: Antifungal activity of amidocoumarins
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compounds showed moderate to excellent in vitro activities against 
different Gram-positive, Gram-negative bacterial strains, and fungi with 
MIC values between 6.25 and 50 mg/mL. Compound 21 was found to 
be the most active with MIC 6.25 μg/mL against B. pumilus, S. aureus, 
and S. typhi. Compound 21 also inhibited the growth of fungi C. albicans 
and C. tropicalis at concentration 12.5 and 25 μg/mL, respectively. 
The other promising antibacterial molecules from this series were 
compounds 9, 11, and 23. These compounds showed broad-spectrum 
activity against both bacterial and fungal strains. Compound 9 emerged 
as best chitinase inhibitor of the series. Our findings suggest that the 
further derivatization of the amidocoumarin scaffold could give rise to 
structures with enhanced antimicrobial and anti-chitinase activities.
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